Intelligent Bio Solutions (NASDAQ:INBS), Inc. (NASDAQ: INBS) is a life sciences technology company headquartered in Hillsborough, North Carolina. Founded in 2002, the company specializes in the development and commercialization of digital microfluidics-based diagnostic and sample preparation platforms. Its proprietary Droplet Interface for Automated Sample Preparation (DIAS) technology enables precise manipulation of minute fluid volumes, supporting a range of applications from molecular diagnostics to bioprocess monitoring.
The company’s product portfolio includes disposable microfluidic cartridges and companion benchtop instruments designed for rapid, sample-to-answer testing. One of its early commercial successes involved automated detection and removal of mycoplasma contamination in cell cultures, a critical quality control step for research laboratories and biomanufacturing facilities. More recently, Intelligent Bio Solutions has expanded its assay menu to include infectious disease markers, antibody detection and other targeted molecular assays under development for point-of-care and centralized laboratory settings.
Serving a diverse customer base in the United States, Europe and Asia, Intelligent Bio Solutions partners with academic research institutions, pharmaceutical developers and contract research organizations. The company’s flexible manufacturing facilities and collaborative development model allow it to support both small-batch research testing and larger-scale production runs. By leveraging its microfluidics expertise, the firm aims to reduce assay turnaround times and improve automation in workflows across life science and clinical diagnostics markets.
Leadership at Intelligent Bio Solutions brings together seasoned professionals in diagnostics, engineering and commercial strategy. The executive team is focused on expanding the company’s DIAS platform licensing programs while advancing internal R&D projects toward regulatory clearance. With a continuing emphasis on innovation in sample handling and assay integration, the company is positioned to address evolving needs in precision medicine, biomanufacturing quality control and decentralized testing.
